H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Eloxx Pharmaceuticals Inc (ELOX) today and set a price target of $10. The company’s shares closed on Friday at $11.68.
Fein wrote:
“Our price target of $10/share is based on an equally-weighted composite of: (a) $9.01/share, as a 35x multiple of taxed and diluted $2.75 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $10.75/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 47.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Eloxx Pharmaceuticals Inc with a $10 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.60 and a one-year low of $8. Currently, Eloxx Pharmaceuticals Inc has an average volume of 32.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments.
